Cell Biol Int 2018 Jul 14;42(7):781-793. Epub 2018 May 14.
Department of Medical Oncology, The First Hospital of China Medical University, Shenyang, 110001, China.
Download full-text PDF
Cancer Lett 2008 Dec 6;272(2):296-306. Epub 2008 Sep 6.
Department of Internal Medicine, Seoul National University College of Medicine, 28 Yongon-dong, Chongno-gu, Seoul 110-744, Republic of Korea.
HER2 overexpression is observed in 5-25% of gastric cancers. Lapatinib is a dual inhibitor of the epidermal growth factor receptor and HER2 tyrosine kinase. We examined the antitumor effect of lapatinib in gastric cancer cell lines. Read More
Mol Cancer Ther 2012 Mar 11;11(3):660-9. Epub 2012 Jan 11.
Department of Surgery, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA.
HER2 amplification is found in more than 15% of gastric cancers and is associated with poor clinical outcome. Lapatinib, a dual HER2 and epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, has shown promising in vitro results in treating HER2(+) cancer cells. However, several studies have shown that activation of alternative receptor tyrosine kinases can mediate resistance to HER-targeted therapy. Read More
Mol Cell Biochem 2017 Dec 1;436(1-2):29-38. Epub 2017 Jun 1.
Department of Medical Oncology, The First Hospital of China Medical University, Shenyang, 110001, People's Republic of China.
The ATR/checkpoint kinase 1 (Chk1) pathway plays an essential role in modulating the DNA damage response and homologous recombination. Particularly, Chk1 phosphorylation is related to cancer prognosis and therapeutic resistance. Some receptor tyrosine kinases participate in the regulation of Chk1 phosphorylation; however, the effect of hepatocyte growth factor (HGF) on Chk1 phosphorylation is unknown. Read More
Oncogene 2014 Jun 22;33(25):3334-41. Epub 2013 Jul 22.
1] Cancer Research Institute, Seoul National University College of Medicine, Seoul, Republic of Korea  Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Republic of Korea  WCU Department of Molecular Medicine and Biopharmaceutical Sciences, Seoul National University College of Medicine, Seoul, Republic of Korea.
Human epidermal growth factor receptor 2 (HER2)-directed treatment using trastuzumab has shown clinical benefit in HER2-positive gastric cancer. Clinical trials using lapatinib in HER2-positive gastric cancer are also currently underway. As with other molecularly targeted agents, the emergence of acquired resistance to HER2-directed treatment is an imminent therapeutic problem for HER2-positive gastric cancer. Read More